



ROBERT BENTLEY
Governor

Alabama Medicaid Agency

501 Dexter Avenue
P.O. Box 5624
Montgomery, Alabama 36103-5624

www.medicaid.alabama.gov
e-mail: almedicaid@medicaid.alabama.gov

Telecommunication for the Deaf: 1-800-253-0799
334-242-5000 1-800-362-1504



STEPHANIE MCGEE AZAR
Acting Commissioner

PUBLIC NOTICE

SUBJECT: AMENDMENT TO THE ALABAMA STATE PLAN FOR MEDICAL ASSISTANCE

The Alabama Medicaid Agency is proposing to amend its State Plan for Medical Assistance through a State Plan Amendment. This amendment will remove barbiturates, benzodiazepines and agents used to promote smoking cessation from the list of drugs the Medicaid program may exclude or restrict from coverage. These changes are being made in accordance with Centers for Medicare and Medicaid Services (CMS) Program Notices.

A copy of the proposed changes will be made available upon request for public review at each county office of the Department of Human Resources and the State Office of the Alabama Medicaid Agency.

Written comments concerning these changes are welcome and should be mailed to: Administrative Secretary, Alabama Medicaid Agency, 501 Dexter Avenue, P. O. Box 5624, Montgomery, Alabama 36103-5624. All written comments will be available for review by the public during normal business hours at the above address.

Stephanie McGee Azar
Acting Commissioner

REC'D & FILED

DEC 17 2013

LEGISLATIVE REF SERVICE

Limitation of Services

Prescribed drugs, dentures, and prosthetic devices; and eyeglasses prescribed by a physician skilled in diseases of the eye or by an optometrist.

12. a. **Prescribed Drugs**

- (e) Prescription vitamins and mineral products, except prenatal vitamins and fluoride preparations and others as specified by the Alabama Medicaid Agency.
 - Renal vitamins and vitamin preparations used in Total Parenteral Nutrition are covered.
- (f) Non prescription drugs except for those specified by the Alabama Medicaid Agency.
 - Insulins and second generation antihistamines are covered; smoking cessation products are covered for Plan First recipients and pregnant females.
- (g) Covered outpatient drugs which the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or its designee.
- ~~(h) Barbiturates except for generic barbiturates and for dual eligible individuals effective January 1, 2013 when used in the treatment of epilepsy, cancer or a chronic mental health disorder as Part D will cover those indications.~~
- ~~(i) Benzodiazepines except for generic benzodiazepines (except estazolam) and for dual eligible individuals effective January 1, 2013 as Part D will cover all indications~~
- ~~(j) Agents when used to promote smoking cessation unless authorized for pregnant females women according to the Public Health Service guidelines "Treating Tobacco Use and Dependence: 2008 Update: A Clinical Practice Guideline, or any subsequent modification of such guideline.~~